MiR-340 inhibition of breast cancer cell migration and invasion through targeting of oncoprotein c-Met

Cancer

Volumn 117, Issue 13, 2011, Pages 2842-2852

  Wu, Zheng Sheng ^a,b   Wu, Qiang ^b   Wang, Chao Qun ^b   Wang, Xiao Nan ^b   Huang, Jing ^b   Zhao, Jing Jing ^a   Mao, Shan Shan ^a   Zhang, Gui Hong ^b   Xu, Xiao Chun ^b,c   Zhang, Nong ^a  

^a FUDAN UNIVERSITY   (China)

^b ANHUI MEDICAL UNIVERSITY   (China)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

biomarker; breast cancer; microRNA; prognosis; tumor cell invasion

Indexed keywords

GELATINASE A; GELATINASE B; MICRORNA; MICRORNA 340; SCATTER FACTOR RECEPTOR; UNCLASSIFIED DRUG;

ARTICLE; BREAST CANCER; CANCER CELL; CANCER GRADING; CANCER STAGING; CANCER SURVIVAL; CELL GROWTH; CELL INVASION; CELL MIGRATION; CONTROLLED STUDY; DOWN REGULATION; EX VIVO STUDY; HUMAN; HUMAN CELL; HUMAN TISSUE; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL MOVEMENT; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IN SITU HYBRIDIZATION; LYMPHATIC METASTASIS; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM STAGING; POLYMERASE CHAIN REACTION; PROTO-ONCOGENE PROTEINS C-MET; RECEPTORS, GROWTH FACTOR; RNA, SMALL INTERFERING; SURVIVAL RATE;

EID: 79959624589     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.25860     Document Type: Article

References (44)

1. Jemal A, Siegel R, Xu J, Ward E., Cancer Statistics. CA Cancer J Clin. 2010; 60: 277-300.
2. Weigelt B, Peterse JL, van 't Veer LJ., Breast cancer metastasis: markers and models. Nat Rev Cancer. 2005; 5: 591-602. (Pubitemid 41081385)
3. Bartel DP., MicroRNAs: target recognition and regulatory functions. Cell. 2009; 136: 215-233.
4. Kloosterman WP, Plasterk RH., The diverse functions of microRNAs in animal development and disease. Dev Cell. 2006; 11: 441-450. (Pubitemid 44430905)
5. Baranwal S, Alahari SK., miRNA control of tumor cell invasion and metastasis. Int J Cancer. 2010; 126: 1283-1290.
6. Bartels CL, TsongalisGJ. MicroRNAs: novel biomarkers for human cancer. Clin Chem. 2009; 55: 623-631.
7. Esquela-Kerscher A, Slack FJ., Oncomirs-microRNAs with a role in cancer. Nat Rev Cancer. 2006; 6: 259-269.
8. Zhang H, Li Y, Lai M., The microRNA network and tumor metastasis. Oncogene. 2010; 29: 937-948.
9. Garzon R, Calin GA, Croce CM., MicroRNAs in Cancer. Annu Rev Med. 2009; 60: 167-179.
10. Iorio MV, Croce CM., MicroRNAs in cancer: small molecules with a huge impact. J Clin Oncol. 2009; 27: 5848-5856.
11. Tavazoie SF, Alarcon C, Oskarsson T, et al. Endogenous human microRNAs that suppress breast cancer metastasis. Nature. 2008; 451: 147-152.
12. Ma L, Teruya-Feldstein J, Weinberg RA., Tumour invasion and metastasis initiated by microRNA-10b in breast cancer. Nature. 2007; 449: 682-688. (Pubitemid 47552092)
13. Wu ZS, Wu Q, Wang CQ, et al. MiR-339-5p inhibits breast cancer cell migration and invasion in vitro and may be a potential biomarker for breast cancer prognosis. BMC Cancer. 2010; 10: 542.
14. Tavassoli EF, Devilee P., WHO: Pathology and Genetics, Tumors of the Breast and Female Genital Organs. Lyon, France: IARC Press; 2003: 10.
15. Elston CW, Ellis IO., Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology. 1991; 19: 403-410.
16. Wu ZS, Wu Q, Yang JH, et al. Prognostic significance of MMP-9 and TIMP-1 serum and tissue expression in breast cancer. Int J Cancer. 2008; 122: 2050-2056. (Pubitemid 351441195)
17. Hu Y, Correa AM, Hoque A, et al. Prognostic significance of differentially expressed miRNAs in esophageal cancer. Int J Cancer. 2011; 128: 132-143.
18. Qi L, Bart J, Tan LP, et al. Expression of miR-21 and its targets (PTEN, PDCD4, TM1) in flat epithelial atypia of the breast in relation to ductal carcinoma in situ and invasive carcinoma. BMC Cancer. 2009; 9: 163.
19. Graveel CR, DeGroot JD, Su Y, et al. Met induces diverse mammary carcinomas in mice and is associated with human basal breast cancer. Proc Natl Acad Sci U S A. 2009; 106: 12909-12914.
20. Song S, Lippman SM, Zou Y, Ye X, Ajani JA, Xu XC,. Induction of cyclooxygenase-2 by benzo [a]pyrene diol epoxide through inhibition of retinoic acid receptor-beta 2 expression. Oncogene. 2005; 24: 8268-8276. (Pubitemid 43250919)
21. Lewis BP, Burge CB, Bartel DP., Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell. 2005; 120: 15-20. (Pubitemid 40094598)
22. Tuck AB, Park M, Sterns EE, Boag A, Elliott BE., Co-expression of hepatocyte growth factor and receptor (met) in human breast carcinoma. Am J Pathol. 1996; 148: 225-232. (Pubitemid 26022451)
23. Beviglia L, Matsumoto K, Lin CS, Ziober BL, Kramer RH., Expression of the c-met/HGF receptor in human breast carcinoma: correlation with tumor progression. Int J Cancer. 1997; 74: 301-309. (Pubitemid 27321800)
24. Tuck AB, Elliott BE, Hota C, Tremblay E, Chambers AF., Osteopontin-induced, integrin-dependent migration of human mammary epithelial cells involves activation of the hepatocyte growth factor receptor (Met). J Cell Biochem. 2000; 78: 465-475. (Pubitemid 30491074)
25. Jiang WG, Grimshaw D, Lane J, et al. A hammerhead ribozyme suppresses expression of hepatocyte growth factor/scatter factor receptor c-MET and reduces migration and invasiveness of breast cancer cells. Clin Cancer Res. 2001; 7: 2555-2562. (Pubitemid 32751662)
26. Welm AL, Kim S, Welm BE, Bishop JM., MET and MYC cooperate in mammary tumorigenesis. Proc Natl Acad Sci U S A. 2005; 102: 4324-4329. (Pubitemid 40397110)
27. Garcia S, Dales JP, Charafe-Jauffret E, et al. Poor prognosis in breast carcinomas correlates with increased expression of targetable CD146 and c-Met and with proteomic basal-like phenotype. Hum Pathol. 2007; 38: 830-841. (Pubitemid 46726507)
28. Ponzo MG, Lesurf R, Petkiewicz S, et al. Met induces mammary tumors with diverse histologies and is associated with poor outcome and human basal breast cancer. Proc Natl Acad Sci U S A. 2009; 106: 12903-12908.
29. Klein CA., Cancer. The metastasis cascade. Science. 2008; 321: 1785-1787.
30. Nicoloso MS, Spizzo R, Shimizu M, Rossi S, Calin GA., MicroRNAs-the micro steering wheel of tumour metastases. Nat Rev Cancer. 2009; 9: 293-302.
31. Huang Q, Gumireddy K, Schrier M, et al. The microRNAs miR-373 and miR-520c promote tumour invasion and metastasis. Nat Cell Biol. 2008; 10: 202-210. (Pubitemid 351194050)
32. Wu H, Zhu S, Mo YY., Suppression of cell growth and invasion by miR-205 in breast cancer. Cell Res. 2009; 19: 439-448.
33. Hurst DR, Edmonds MD, Scott GK, Benz CC, Vaidya KS, Welch DR., Breast cancer metastasis suppressor 1 up-regulates miR-146, which suppresses breast cancer metastasis. Cancer Res. 2009; 69: 1279-1283.
34. Gherardi E, Stoker M., Hepatocyte and scatter factor. Nature. 1990; 346: 228.
35. Peruzzi B, Bottaro DP., Targeting the c-Met signaling pathway in cancer. Clin Cancer Res. 2006; 12: 3657-3660. (Pubitemid 44000247)
36. Birchmeier C, Birchmeier W, Gherardi E, Vande Woude GF., Met, metastasis, motility and more. Nat Rev Mol Cell Biol. 2003; 4: 915-925. (Pubitemid 37493640)
37. Zhou HY, Wong AS., Activation of p70S6K induces expression of matrix metalloproteinase 9 associated with hepatocyte growth factor-mediated invasion in human ovarian cancer cells. Endocrinology. 2006; 147: 2557-2566.
38. Naka T, Boltze C, Samii A, et al. Expression of c-MET, low-molecular-weight cytokeratin, matrix metalloproteinases-1 and -2 in spinal chordoma. Histopathology. 2009; 54: 607-613.
39. Kermorgant S, Aparicio T, Dessirier V, Lewin MJ, Lehy T., Hepatocyte growth factor induces colonic cancer cell invasiveness via enhanced motility and protease overproduction. Evidence for PI3 kinase and PKC involvement. Carcinogenesis. 2001; 22: 1035-1042. (Pubitemid 32633601)
40. Rydlova M, Holubec L, Jr, Ludvikova M, Jr, et al. Biological activity and clinical implications of the matrix metalloproteinases. Anticancer Res. 2008; 28: 1389-1397. (Pubitemid 351578885)
41. Roy R, Yang J, Moses MA., Matrix metalloproteinases as novel biomarkers and potential therapeutic targets in human cancer. J Clin Oncol. 2009; 27: 5287-5297.
42. Baffa R, Fassan M, Volinia S, et al. MicroRNA expression profiling of human metastatic cancers identifies cancer gene targets. J Pathol. 2009; 219: 214-221.
43. Weber MJ., New human and mouse microRNA genes found by homology rearch. FEBS J. 2005; 272: 59-73. (Pubitemid 40083067)
44. Zhang H, Su SB, Zhou QM, Lu YY., Differential expression profiles of microRNAs between breast cancer cells and mammary epithelial cells. Ai Zheng. 2009; 28: 493-499.